SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced the presentation of new data from the Phase I clinical study of its pioneering therapy, SCG101, at the 2024 AASLD Liver Meeting. SCG101 is an autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy that targets hepatitis B surface antigen (HBsAg).
Significant Reduction in Serum HBsAg Levels Observed
In the study, 12 patients were treated with a single intravenous dose of SCG101, ranging from 5.0×10^7 to 1.0×10^8 TCR+ T cells/kg. The results showed a significant reduction in serum HBsAg levels among all patients. Specifically, 11 out of 12 (92%) patients achieved a reduction of 1.0 to 4.6 log10, and the levels remained below 100 IU/mL throughout the follow-up period, which lasted up to one year.
Notable HBsAg Loss in a Third of Patients
Remarkably, four patients (33%) experienced a loss of HBsAg within 21 days following a single infusion of SCG101, and this loss persisted throughout the follow-up period. This indicates the potential for SCG101 to not only reduce but also eliminate HBsAg in a significant portion of treated patients, offering a new hope for the treatment of hepatitis B.-Fineline Info & Tech
